« Return to News | R&D Trends

Recipharm, Synthonics to promote novel drug delivery technology

Wednesday, May 8, 2013 09:40 AM

Recipharm Pharmaceutical, a Swedish contract development and manufacturing organization (CDMO), and Synthonics, a specialty pharmaceutical company based in Blacksburg, Va., have formed a Joint Promotion Agreement.

Synthonics has developed a proprietary metal coordination chemistry that can significantly improve a compound’s delivery and absorption. The contract, the first of its kind to be entered into between the pair, will provide Recipharm customers full access to Synthonics’ metal coordination chemistry, improving the delivery and performance of their compounds. Recipharm provides services that assist pharmaceutical companies throughout Europe, the U.S., Japan and further afield with the development and formulation of products. 

“We are pleased to partner with Synthonics to expand the services and solutions that we can offer our clients,” said Maria Lundberg, general manager of Recipharm. “The application of Synthonics’ chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products. Furthermore, our ability to offer such services through this novel partnership distinguishes us from other CDMOs.”

Ken Slepicka, CEO of Synthonics, said, “Synthonics is delighted to partner with Recipharm to help advance promising molecules to market.  We are very impressed with Recipharm’s formulation and development teams and believe that our chemistry will fit well in their existing tool kit of solutions. We expect this agreement to help us reach new clients and to expand the use of our chemistry.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.